Unlike PD-L1 negative regulators (HDAC1, HDAC2, and HDAC3), the expression ranks of PD-L1 and its positive regulators (EP300, CREBBP, IRF-1, and BRD4) negatively correlated to Grade Group in another study, suggesting an increase of function during cancer progression [116]. Here, EP300 is linked to cancer.